FLGR-242 for Muscle Growth - Quick Reference Sheet
evipedia.ai
← Back

FLGR-242 for Muscle Growth

Created on 09/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A laboratory-made protein that releases the body's brake on muscle growth. Nothing published describes what it does in a person or animal; every claim comes from the seller. Related compounds add muscle tissue but not strength, bringing cramping, loose stools, a rise in a blood fat linked to artery disease, and nosebleeds with the broadest-acting versions. Supply is frequently impure. (Full Review)

Protocol

No validated protocol exists
No defined dose
No regulator, clinic or published study has defined a dose. What circulates comes from vendors and resellers.
Circulated dose ranges
100–300 mcg daily to 5 mg every other day
A roughly hundredfold spread that reveals guesswork rather than a converging practice.
Route and site
Subcutaneous, abdominal
What vendors describe. Intramuscular delivery is what the two follistatin-based clinical agents used.
Time to effect
Skeletal muscle mass
Within 4 weeks
Related agents produced measurable lean-mass change within four weeks and plateaued near six months. A scan before starting and one at twelve weeks is what assessment requires.
Fat mass
48 weeks
Measured over 48 weeks with bimagrumab, an antibody, not with any follistatin-derived agent.
Glucose handling
48 weeks
Glycated hemoglobin fell over 48 weeks in a randomized bimagrumab trial in type 2 diabetes. Never measured for FLGR-242.

Benefits

Contraindications
  • Active malignancy, or cancer treated within the past 5 years
  • Pregnancy, lactation, or active attempts to conceive
  • Hereditary hemorrhagic telangiectasia, or any bleeding disorder (platelets below 100 × 10⁹/L, international normalized ratio above 1.5)
  • Chronic kidney disease (estimated glomerular filtration rate below 30 mL/min/1.73 m²)
  • Liver impairment (Child-Pugh Class B or C)
  • Heart failure (New York Heart Association Class III or IV), or myocardial infarction within 90 days
  • Adults under 25, or anyone whose growth plates have not closed
  • Competitive athletes in any sport subject to anti-doping testing
  • Anyone unable to obtain third-party identity, purity and endotoxin certification for the specific batch
Key Interactions
  • Anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel): Caution
  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Caution
  • Glucagon-like peptide-1 receptor agonists (semaglutide, tirzepatide): Monitor
  • Systemic corticosteroids (prednisone, dexamethasone): Monitor
  • Androgens and anabolic steroids (testosterone, nandrolone, oxandrolone): Caution
  • Statins (atorvastatin, rosuvastatin): Monitor
  • Supplements with additive effects on this pathway (creatine monohydrate, epicatechin, ecdysteroids, urolithin A): Monitor
  • Supplements with additive bleeding effects (high-dose fish oil, ginkgo, garlic extract, vitamin E, nattokinase): Caution
  • Other interventions (resistance training, caloric restriction, blood-flow-restriction training): Potentiating rather than hazardous

Risk & Side Effects

  • Low: Muscle cramps and spasms; diarrhea; rise in low-density lipoprotein cholesterol; nosebleeds and dilated skin vessels; injection-site reactions and hypersensitivity; exposure to impure or misrepresented product
  • Speculative: Immunogenicity and neutralizing antibodies; reduced force per unit of muscle; disruption of reproductive hormone signaling; effects on bone; unopposed growth signaling in non-muscle tissue; cardiac remodeling

Monitoring

Marker Target Why
Lean body mass (DXA scan) No established target; ≥1 kg gain from own baseline at 12 weeks The primary outcome the compound is bought for
Apolipoprotein B <80 mg/dL; <60 mg/dL for those prioritizing arterial risk Counts artery-damaging particles; this class raises them
LDL cholesterol <70 mg/dL (1.8 mmol/L) Directly raised by pooled trials of this class
Platelet count 175–350 × 10⁹/L Falling platelets amplify the bleeding signal of this class
Hemoglobin 13.5–15.0 g/dL (women), 14.0–16.0 g/dL (men) Detects hidden blood loss from the nosebleed and telangiectasia signal
Creatine kinase 50–200 U/L Separates drug-related cramps from genuine muscle damage
Alanine aminotransferase <25 U/L Baseline organ safety for an uncharacterized injected protein
Estimated glomerular filtration rate >90 mL/min/1.73 m² Clearance route for protein breakdown products
Fasting insulin 2–5 µIU/mL Tracks the metabolic effect claimed for this pathway
Glycated hemoglobin 4.9–5.3% Confirms whether added muscle improves glucose handling
Follicle-stimulating hormone 1.5–8.0 IU/L (men), cycle-dependent (women) Detects activin blockade, the off-target effect the design claims to avoid
Grip and knee-extensor strength ≥5% gain from own baseline at 12 weeks The endpoint that related agents repeatedly failed to move

Cadence: Full baseline panel before any exposure; short-interval safety check at 2 weeks; lipids and blood count at 6 weeks; body composition and strength at 12 weeks; everything again at 6 months; thereafter the same full panel every 3–6 months.

Qualitative Assessment

  • Cramping frequency and timing, particularly at night
  • Stool consistency and frequency in the first four weeks
  • Nosebleeds, easy bruising, or new spider-like vessels on the face and trunk
  • Perceived recovery between training sessions and session-to-session load tolerance
  • Fit of clothing at the shoulders and thighs relative to the waist
  • Injection-site redness, swelling or persistent nodules
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.